Search results for "Pulmonary Disease"

showing 10 items of 360 documents

[Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC study): method and organisation].

2010

There is little information regarding the clinical management of hospital inpatients diagnosed with exacerbation of Chronic Obstructive Pulmonary Disease (COPD). AUDIPOC is a clinical audit dealing with the clinical management of COPD in Spain.To examine the adequacy and validity of the instruments used to measure the variables proposed by AUDIPOC Spain (Preliminary Study) and to verify the viability of AUDIPOC in a complex environment with hospitals of different sizes, resources, and organizational layout (Pilot Study).The Preliminary Study took place in 4 hospitals and studied 213 cases. The Pilot Study took place in 30 hospitals of 6 Autonomous Communities (i.e. Regions) and studied 1203…

Clinical auditMalemedicine.medical_specialtyExacerbationPulmonary diseasePilot ProjectsPulmonary Disease Chronic ObstructivePatient AdmissionCatchment Area HealthmedicineHumansMulticenter Studies as TopicProspective StudiesIntensive care medicineCOPDMedical Auditbusiness.industryHospitals PublicGeneral Medicinemedicine.diseaserespiratory tract diseasesHospitalizationCross-Sectional StudiesResearch DesignSpainFemalebusinessFollow-Up StudiesArchivos de bronconeumologia
researchProduct

Counseling intervention to improve quality of life in patients with pre-existing acute myocardial infarction (AMI) or chronic obstructive pulmonary d…

2018

In the light of diagnostic and therapeutic advances, patients with a previous myocardial infarction or with a diagnosis of chronic obstructive pulmonary disease are vulnerable and need continuous monitoring over time. These pathological frameworks have a strong impact on the economy and on the status of the population and require effective and low-cost solutions.The objective of this clinical trial is to evaluate the efficacy in the short term of a telephone counseling intervention to modify the lifestyles of these two patient populations.In May 2015, all the patients included in the study underwent a questionnaire to evaluate their eating and smoking habits and their quality of life. After…

CounselingQuality of lifeChronic Obstructiveenvironmental and occupational healthChronic obstructive pulmonary diseaseTertiary preventionpublic healthMyocardial InfarctionPilot Projectsacute myocardial infarction; chronic disease; chronic obstructive pulmonary disease; counseling; nutrition; quality of life; smoke; tertiary prevention; public health environmental and occupational health; infectious diseasesAcute myocardial infarctioninfectious diseasesAcute myocardial infarction; Chronic disease; Chronic obstructive pulmonary disease; Counseling; Nutrition; Quality of life; Smoke; Tertiary preventionChronic diseasePulmonary DiseasePulmonary Disease Chronic ObstructiveSmokeAcute myocardial infarction; Chronic disease; Chronic obstructive pulmonary disease; Counseling; Nutrition; Quality of life; Smoke; Tertiary prevention; Humans; Myocardial Infarction; Pilot Projects; Pulmonary Disease Chronic Obstructive; Quality of Life; CounselingSettore MED/42HumansOriginal ArticlePilot ProjectNutritionHuman
researchProduct

Carbocysteine regulates innate immune responses and senescence processes in cigarette smoke stimulated bronchial epithelial cells

2013

Cigarette smoke represents the major risk factor for chronic obstructive pulmonary disease (COPD). Cigarette smoke extracts (CSE) alter TLR4 expression and activation in bronchial epithelial cells. Carbocysteine, an anti-oxidant and mucolytic agent, is effective in reducing the severity and the rate of exacerbations in COPD patients. The effects of carbocysteine on TLR4 expression and on the TLR4 activation downstream events are largely unknown. This study was aimed to explore whether carbocysteine, in a human bronchial epithelial cell line (16-HBE), counteracted some pro-inflammatory CSE-mediated effects. In particular, TLR4 expression, LPS binding, p21 (a senescence marker), IL-8 mRNA and…

Cyclin-Dependent Kinase Inhibitor p21AgingNeutrophilsPhalloidinAnti-Inflammatory AgentsApoptosisBronchiInflammationBiologyToxicologySettore BIO/09 - FisiologiaAntioxidantsFlow cytometryPulmonary Disease Chronic Obstructivechemistry.chemical_compoundmedicineHumansRNA Messengersenescencebronchial cellscigaretteInnate immune systemmedicine.diagnostic_testCarbocysteineInterleukin-8SmokingEpithelial CellsCell migrationChemotaxisCarbocysteineGeneral MedicineFlow CytometryImmunity InnateCell biologyToll-Like Receptor 4chemistryImmunologyTLR4medicine.symptomInterleukin-1Signal TransductionToxicology Letters
researchProduct

PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.

2004

Phosphodiesterase 4 (PDE4) is a major cyclic AMP-hydrolyzing enzyme in inflammatory and immunomodulatory cells. The wide range of inflammatory mechanisms under control by PDE4 points to this isoenzyme as an attractive target for new anti-inflammatory drugs. Selective inhibitors of PDE4 have demonstrated a broad spectrum of anti-inflammatory activities including the inhibition of cellular trafficking and microvascular leakage, cytokine and chemokine release from inflammatory cells, reactive oxygen species production, and cell adhesion molecule expression in a variety of in vitro and in vivo experimental models. The initially detected side effects, mainly nausea and emesis, appear at least pa…

CyclopropanesChemokineCyclohexanecarboxylic Acidsmedicine.drug_classPhosphodiesterase Inhibitorsmedicine.medical_treatmentAnti-Inflammatory AgentsCarboxylic AcidsAminopyridinesInflammationPharmacologyAnti-inflammatoryPulmonary Disease Chronic ObstructiveIn vivoCell MovementNitrilesmedicineHumansPharmacology (medical)RoflumilastPharmacologybiologyCell adhesion moleculeChemistryCilomilastCyclic Nucleotide Phosphodiesterases Type 4Cytokine3'5'-Cyclic-AMP PhosphodiesterasesImmunologyBenzamidesbiology.proteinmedicine.symptomCell Adhesion Moleculesmedicine.drugPharmacologytherapeutics
researchProduct

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

2013

Background Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), …

CyclopropanesLipopolysaccharidesMaleMAPK/ERK pathwaymedicine.medical_specialtyNeutrophilsPrimary Cell CultureImmunologyDrug ResistanceAminopyridinesGene ExpressionComplex MixturesDexamethasoneHistone DeacetylasesPhosphatidylinositol 3-KinasesPulmonary Disease Chronic ObstructiveGlucocorticoid receptorAdrenal Cortex HormonesInternal medicineTobaccomedicineHumansImmunology and AllergyMacrophage Migration-Inhibitory FactorsDexamethasoneActive metaboliteRoflumilastAgedCOPDbusiness.industryInterleukin-8Drug SynergismMiddle Agedmedicine.diseaseIntramolecular OxidoreductasesEndocrinologyMatrix Metalloproteinase 9BenzamidesMitogen-Activated Protein Kinase PhosphatasesFemaleMacrophage migration inhibitory factorPhosphodiesterase 4 InhibitorsbusinessBiomarkersGlucocorticoidmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

2009

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide. Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency. The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compound. The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500…

CyclopropanesPulmonary and Respiratory MedicinePhosphodiesterase Inhibitorsmedicine.drug_classDrug Evaluation PreclinicalAdministration OralAminopyridinesInflammationPharmacologyPulmonary Disease Chronic ObstructiveCOPD; Inflammation; Oral therapy; Phosphodiesterase 4; Preclinical pharmacology; RoflumilastBronchodilatormedicineAnimalsHumansCOPDPharmacology (medical)RoflumilastPhosphodiesterase 4InflammationCOPDLungOral therapybusiness.industryAnti-Inflammatory Agents Non-SteroidalBiochemistry (medical)medicine.diseasePulmonary hypertensionObstructive lung diseasemedicine.anatomical_structureTolerabilityBenzamidesImmunologyPhosphodiesterase 4 InhibitorsPreclinical pharmacologymedicine.symptombusinessRoflumilastmedicine.drug
researchProduct

Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa

2017

Aim: The bronchial microbiome of severe chronic obstructive pulmonary disease patients colonized by Pseudomonas aeruginosa was analyzed using 16S rRNA gene sequencing to identify differences related to biofilm-forming capacity. Patients & methods: Patient sputum samples from 21 patients were studied. Results: Statistically significant differences related to biofilm-forming capacity were only found for genera with relative abundances <1%, and Fusobacterium was over-represented when biofilm-forming capacity was high. Genera with relative abundances >50% which increased from baseline were observed in 10/14 exacerbations, but corresponded to Pseudomonas only in three episodes, while …

DNA Bacterial0301 basic medicineMicrobiology (medical)Lung microbiomeExacerbation030106 microbiologyBronchiSevere copdmedicine.disease_causeDNA RibosomalMicrobiologyMicrobiologyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineRNA Ribosomal 16SmedicineHumansPseudomonas InfectionsMicrobiomebiologyPseudomonas aeruginosaMicrobiotaPseudomonasSputumBiofilmSequence Analysis DNAbiology.organism_classification030228 respiratory systemBiofilmsPseudomonas aeruginosaSputummedicine.symptomFuture Microbiology
researchProduct

Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa

2014

The bronchial microbiome in severe COPD during stability and exacerbation in patients chronically colonised by Pseudomonas aeruginosa (PA), has not been defined. Our objective was to determine the characteristics of the bronchial microbiome of severe COPD patients colonised and not colonised by P. aeruginosa and its changes during exacerbation. COPD patients with severe disease and frequent exacerbations were categorised according to chronic colonisation by P. aeruginosa. Sputum samples were obtained in stability and exacerbation, cultured, and analysed by 16S rRNA gene amplification and pyrosequencing. Sixteen patients were included, 5 of them showing chronic colonisation by P. aeruginosa.…

DNA BacterialMaleMicrobiology (medical)ExacerbationMolecular Sequence DataBronchiBiologymedicine.disease_causeDNA RibosomalArticleMicrobiologyCohort StudiesPulmonary Disease Chronic ObstructiveRNA Ribosomal 16SHaemophilusmedicineCluster AnalysisHumansMicrobiomeMoraxellaPhylogenyAgedAged 80 and overStreptococcusPseudomonas aeruginosaMicrobiotaSputumGeneral MedicineSequence Analysis DNAMiddle Agedbiology.organism_classificationrespiratory tract diseasesColonisationInfectious DiseasesSputumFemalemedicine.symptomEuropean Journal of Clinical Microbiology & Infectious Diseases
researchProduct

Analysis of microbiota in stable patients with chronic obstructive pulmonary disease

2014

To identify the bacterial diversity (microbiota) in expectorated sputum, a pyrosequencing method that investigates complex microbial communities of expectorated sputum was done in 19 stable chronic obstructive pulmonary disease patients (mean (SD) FEV1: 47 (18%) of predicted value). Using conventional culture, 3 phyla and 20 bacterial genera were identified, whereas the pyrosequencing approach detected 9 phyla and 43 genera (p < 0.001). In sputum the prevalent genera with pyrosequencing approach were Streptococcus, Actinomyces, Neisseria, Haemophilus, Rothia, Fusobacterium, Gemella, Granulicatella, Porphyromonas, Prevotella and Veillonella. Enterobacteriaceae, detected frequently in convent…

DNA BacterialMaleMicrobiology (medical)VeillonellaPolymerase Chain ReactionPathology and Forensic MedicineMicrobiologyPulmonary Disease Chronic ObstructiveRNA Ribosomal 16SHaemophilusPrevotellamedicineHumansImmunology and AllergyProspective StudiesMoraxellaAgedAged 80 and overBacteriabiologyMicrobiotaSputumGeneral MedicineMiddle Agedbiology.organism_classificationBacterial Typing TechniquesMolecular TypingRNA BacterialFusobacteriumGemellaImmunologyMetagenomeSputumFemalemedicine.symptomActinomycesAPMIS
researchProduct